{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:41:58Z","timestamp":1777984918701,"version":"3.51.4"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie GK"},{"name":"Asahi Kasei"},{"DOI":"10.13039\/100020830","name":"Ayumi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020830","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen K.K."},{"name":"Ono"},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taisho"},{"name":"Teijin Healthcare"},{"name":"UCB Japan"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Anti-SS-A (Ro) antibody-positive rheumatoid arthritis (RA) constitutes a clinically important subgroup, but its impact on retention of biologic or targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs) across different modes of action (MOA) and reasons for discontinuation remains unclear. We conducted a multicenter retrospective analysis of the Japanese ANSWER cohort, including RA patients who started or switched b\/tsDMARDs between 2011 and 2024 and had baseline anti-SS-A antibody testing. Among 1,452 patients (2,703 treatment courses), 255 patients (17.6%) were anti\u2013SS-A antibody positive (507 courses, 18.8%). Propensity score matching balanced baseline characteristics, and drug retention was evaluated using Kaplan\u2013Meier and competing risk analyses. Overall discontinuation was analyzed using Cox proportional hazards models, and Fine\u2013Gray subdistribution hazards models were used for discontinuation by reason and for adverse event\u2013related discontinuation stratified by MOA. After matching, 507 treatment courses from 255 anti-SS-A antibody-positive patients and 1,014 courses from 628 antibody-negative patients were analyzed. Anti-SS-A antibody positivity was not associated with overall b\/tsDMARD retention (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.91\u20131.26, p\u2009=\u20090.382). In MOA-stratified analyses, positivity showed a trend toward increased discontinuation with interleukin-6 (IL-6) receptor inhibitors and cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4-Ig). In competing-risk analyses, discontinuation due to adverse events was significantly more frequent in antibody-positive patients (subdistribution hazard ratio [sHR] 1.80, 95% CI 1.28\u20132.52; p\u2009=\u20090.000685). Among adverse event-related discontinuations, anti-SS-A antibody positivity was associated with higher risks with IL-6 receptor inhibitors (sHR 2.41, 95% CI 1.24\u20134.71; p\u2009=\u20090.0098) and tumor necrosis factor (TNF) inhibitors (sHR 2.04, 95% CI 1.22\u20133.40; p\u2009=\u20090.0066), but not with CTLA4-Ig or Janus kinase (JAK) inhibitors. These findings suggest that treatment tolerability, rather than overall efficacy, may be a key determinant of b\/tsDMARD survival in anti-SS-A antibody-positive RA and that MOA- and cause-specific profiles should be considered when selecting therapies in this subgroup.<\/jats:p>","DOI":"10.1371\/journal.pone.0344747","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:29:16Z","timestamp":1773854956000},"page":"e0344747","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-5249","authenticated-orcid":true,"given":"Kazuma","family":"Nishisaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-5728","authenticated-orcid":true,"given":"Takaichi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tsubosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kamenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-1273","authenticated-orcid":true,"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Katsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iku","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-341X","authenticated-orcid":true,"given":"Sho","family":"Sendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-3743","authenticated-orcid":true,"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"7","key":"pone.0344747.ref001","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.autrev.2025.103820","article-title":"Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases","volume":"24","author":"S Wu","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"5","key":"pone.0344747.ref002","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s10787-025-01756-4","article-title":"Ocimene mitigates pyroptosis through TLR4\/NLRP3-mediated mechanisms in CFA-induced inflammation","volume":"33","author":"I Laraib","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"1","key":"pone.0344747.ref003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10822-025-00595-3","article-title":"MiR-146\/TNF-\u03b1\/IL-6\/osteocalcin crosstalk in anti-rheumatic potential of Galleria mellonella hemolymph from computational molecular modeling to in-vivo validation","volume":"39","author":"SM Ahmed","year":"2025","journal-title":"J Comput Aided Mol Des"},{"key":"pone.0344747.ref004","doi-asserted-by":"crossref","first-page":"152721","DOI":"10.1016\/j.semarthrit.2025.152721","article-title":"Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk","volume":"73","author":"S-H You","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"pone.0344747.ref005","article-title":"Poor sleep and high rheumatoid arthritis risk: Evidence from large UK Biobank cohort","volume":"20","author":"Y-Q Yang","year":"2025","journal-title":"PLoS One"},{"key":"pone.0344747.ref006","doi-asserted-by":"crossref","first-page":"1398314","DOI":"10.3389\/fimmu.2024.1398314","article-title":"Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy","volume":"15","author":"C Perricone","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0344747.ref007","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14712598.2024.2358165","article-title":"Non-TNF biologics and their biosimilars in rheumatoid arthritis","volume":"24","author":"TC Mok","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"pone.0344747.ref008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40801-024-00423-4","article-title":"Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study","volume":"11","author":"M Miyashiro","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"pone.0344747.ref009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/17460441.2022.2093852","article-title":"Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis","volume":"17","author":"G Maioli","year":"2022","journal-title":"Expert Opin Drug Discov"},{"issue":"45","key":"pone.0344747.ref010","article-title":"The Prevalence of Sj\u00f6gren\u2019s Syndrome in Rheumatoid Arthritis Patients and Their Clinical Features","volume":"35","author":"H Kim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"12","key":"pone.0344747.ref011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.13107\/jocr.2024.v14.i12.5002","article-title":"Bilateral Snapping Knee in a Patient with Rheumatoid Arthritis Accompanied by Sj\u00f6gren\u2019s Syndrome - A Case Report","volume":"14","author":"Y Yamasaki","year":"2024","journal-title":"J Orthop Case Rep"},{"issue":"1","key":"pone.0344747.ref012","first-page":"59","article-title":"Anti-Ro\/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations","volume":"24","author":"I Cavazzana","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"pone.0344747.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053910","article-title":"Association of increased frequencies of HLA-DPB1*05:01 with the presence of anti-Ro\/SS-A and anti-La\/SS-B antibodies in Japanese rheumatoid arthritis and systemic lupus erythematosus patients","volume":"8","author":"H Furukawa","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"pone.0344747.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271921","article-title":"Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study","volume":"17","author":"D Waki","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"pone.0344747.ref015","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.101295","article-title":"Anti-Ro\/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis","volume":"38","author":"R Matsudaira","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"pone.0344747.ref016","first-page":"676","article-title":"Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro\/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients","volume":"25","author":"I Cavazzana","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"pone.0344747.ref017","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3109\/14397595.2016.1153567","article-title":"Association of anti-Ro\/SSA antibody with response to biologics in patients with rheumatoid arthritis","volume":"26","author":"S Hagiwara","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0344747.ref018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-025-03514-x","article-title":"Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg\/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study","volume":"27","author":"A Onishi","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"pone.0344747.ref019","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-021-02496-w","article-title":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study","volume":"23","author":"S Jinno","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"pone.0344747.ref020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"O Steinbrocker","year":"1949","journal-title":"J Am Med Assoc"},{"issue":"5","key":"pone.0344747.ref021","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"MC Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0344747.ref022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"pone.0344747.ref023","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"D Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pone.0344747.ref024","first-page":"686","article-title":"Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj\u00f6gren\u2019s syndrome","volume":"30","author":"S Retamozo","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"pone.0344747.ref025","author":"Medical & Biological Laboratories Co., Ltd"},{"key":"pone.0344747.ref026","author":"Department of Clinical Laboratory, Kyoto University Hospital"},{"issue":"446","key":"pone.0344747.ref027","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"JP Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"pone.0344747.ref028","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"PC Austin","year":"2017","journal-title":"Stat Med"},{"key":"pone.0344747.ref029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","article-title":"What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?","volume":"11","author":"P Mehta","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0344747.ref030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40259-024-00648-3","article-title":"Next-Generation Anti-TNF\u03b1 Agents: The Example of Ozoralizumab","volume":"38","author":"K Tsumoto","year":"2024","journal-title":"BioDrugs"},{"issue":"4","key":"pone.0344747.ref031","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis","volume":"29","author":"SS Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"1","key":"pone.0344747.ref032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"T Takeuchi","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"26","key":"pone.0344747.ref033","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","article-title":"Avoiding pitfalls when combining multiple imputation and propensity scores","volume":"38","author":"E Granger","year":"2019","journal-title":"Stat Med"},{"issue":"1","key":"pone.0344747.ref034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03009742.2020.1772361","article-title":"Significance of anti-Ro\/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study","volume":"50","author":"Y Endo","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"pone.0344747.ref035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1060028016682330","article-title":"Reasons for Discontinuation and Adverse Effects of TNF\u03b1 Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis","volume":"51","author":"MH Garc\u00eda-Lagunar","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"2","key":"pone.0344747.ref036","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"M Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0344747.ref037","doi-asserted-by":"crossref","first-page":"814429","DOI":"10.3389\/fimmu.2022.814429","article-title":"The Risk of Adverse Effects of TNF-\u03b1 Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis","volume":"13","author":"B He","year":"2022","journal-title":"Front Immunol"},{"key":"pone.0344747.ref038","doi-asserted-by":"crossref","first-page":"692557","DOI":"10.3389\/fmed.2021.692557","article-title":"Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis","volume":"8","author":"B Hern\u00e1ndez-Breijo","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"pone.0344747.ref039","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-024-03302-z","article-title":"Concomitant Sj\u00f6gren\u2019s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort","volume":"26","author":"L Christ","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"pone.0344747.ref040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13075-020-02189-w","article-title":"Overlapping Sjogren\u2019s syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019","volume":"22","author":"H Zhang","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"pone.0344747.ref041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study","volume":"14","author":"K Ebina","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"pone.0344747.ref042","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00296-025-05859-7","article-title":"Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database","volume":"45","author":"LM Risser","year":"2025","journal-title":"Rheumatol Int"},{"issue":"1","key":"pone.0344747.ref043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-025-03528-5","article-title":"Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study","volume":"27","author":"A \u00d6st\u00f6r","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"pone.0344747.ref044","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10238-025-01578-2","article-title":"Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study","volume":"25","author":"C Baldi","year":"2025","journal-title":"Clin Exp Med"},{"issue":"1","key":"pone.0344747.ref045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/mr\/roac011","article-title":"Abatacept ameliorates both glandular and extraglandular involvements in patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sj\u00f6gren\u2019s Syndrome Endocrinopathy) and ROSE II trials","volume":"33","author":"H Tsuboi","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"6","key":"pone.0344747.ref046","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","article-title":"Effectiveness of abatacept for patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sj\u00f6gren\u2019s syndrome Endocrinopathy) trial","volume":"26","author":"H Tsuboi","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"2","key":"pone.0344747.ref047","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/14397595.2014.951144","article-title":"Efficacy and safety of abatacept for patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sj\u00f6gren\u2019s syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks","volume":"25","author":"H Tsuboi","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"4","key":"pone.0344747.ref048","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"M-J Barrera","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"pone.0344747.ref049","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15176","article-title":"Methotrexate dosage and dosing in Japan","volume":"27","author":"H Kameda","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"pone.0344747.ref050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"H Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0344747.ref051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication","volume":"34","author":"H Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0344747.ref052","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"H Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"6","key":"pone.0344747.ref053","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/s10165-011-0445-4","article-title":"Studies of the efficacy and safety of methotrexate at dosages over 8 mg\/week using the IORRA cohort database","volume":"21","author":"Y Seto","year":"2011","journal-title":"Mod Rheumatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:29:25Z","timestamp":1773854965000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344747"}},"subtitle":[],"editor":[{"given":"Mohammad","family":"Movahedi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344747","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7669680\/v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}